Amarin to Present at SVB Securities Global Biopharma Conference

Rhea-AI Summary

Amarin Corporation plc (NASDAQ:AMRN) announced that CEO Karim Mikhail will participate in the SVB Securities Global Biopharma Conference, scheduled for February 14, 2023, at 10:40 a.m. ET. This virtual conference will span from February 13-16, 2023. The presentation will be available via webcast and will be archived on the company's website.

Amarin focuses on cardiovascular disease management and is committed to advancing treatment options.

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference.

SVB Securities Global Biopharma Conference (February 13-16^th, 2023; Virtual)

Date/Time: February 14, 2023 10:40 a.m. ET

Webcast: https://wsw.com/webcast/svb8/register.aspx?conf=svb8&page=amrn&url=https://wsw.com/webcast/svb8/amrn/1618794

The conference presentation will be webcast live and archived on the Company’s website in the Investor Relations section under Events and Presentations.

About Amarin  

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.  

Availability of Other Information About Amarin

Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information  
Investor Inquiries:   
Investor Relations 
Amarin Corporation plc  
IR@amarincorp.com (investor inquiries) 

Media Inquiries:
Communications   
Amarin Corporation plc   
PR@amarincorp.com (media inquiries)  

FAQ

When will Amarin's CEO present at the SVB Securities Global Biopharma Conference?

Karim Mikhail, Amarin's CEO, will present on February 14, 2023, at 10:40 a.m. ET.

What is the timeframe of the SVB Securities Global Biopharma Conference?

The conference runs from February 13-16, 2023.

Where can I watch the webcast of Amarin's presentation?

The presentation will be available via a webcast and will also be archived on Amarin's website.

What is Amarin's focus in the pharmaceutical industry?

Amarin is focused on managing cardiovascular diseases and advancing treatment options.